Last reviewed · How we verify
Lm-GUCY2C vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Lm-GUCY2C vaccine (Lm-GUCY2C vaccine) — Thomas Jefferson University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lm-GUCY2C vaccine TARGET | Lm-GUCY2C vaccine | Thomas Jefferson University | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lm-GUCY2C vaccine CI watch — RSS
- Lm-GUCY2C vaccine CI watch — Atom
- Lm-GUCY2C vaccine CI watch — JSON
- Lm-GUCY2C vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Lm-GUCY2C vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/lm-gucy2c-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab